Loomis, Sayles & Company’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32K | Buy |
372
+146
| +65% | +$12.8K | ﹤0.01% | 664 |
|
|
2026
Q1 | $20.4K | Sell |
226
-89
| -28% | -$8.17K | ﹤0.01% | 679 |
|
|
2025
Q4 | $28.3K | Sell |
315
-12
| -4% | -$1.14K | ﹤0.01% | 655 |
|
|
2025
Q3 | $32.2K | Buy |
327
+6
| +2% | +$595 | ﹤0.01% | 655 |
|
|
2025
Q2 | $29.3K | Sell |
321
-74
| -19% | -$7.16K | ﹤0.01% | 672 |
|
|
2025
Q1 | $45K | Sell |
395
-213
| -35% | -$22.8K | ﹤0.01% | 638 |
|
|
2024
Q4 | $64K | Buy |
+608
| New | +$65.2K | ﹤0.01% | 620 |
|
|
2024
Q1 | – | Sell |
-65
| Closed | -$8K | – | 995 |
|
|
2023
Q4 | $8K | Sell |
65
-21
| -24% | -$2.34K | ﹤0.01% | 833 |
|
|
2023
Q3 | $10K | Buy |
86
+48
| +126% | +$6.1K | ﹤0.01% | 788 |
|
|
2023
Q2 | $6K | Buy |
+38
| New | +$5.16K | ﹤0.01% | 819 |
|
|
2022
Q3 | – | Sell |
-64
| Closed | -$7K | – | 1064 |
|
|
2022
Q2 | $7K | Hold |
64
| – | – | ﹤0.01% | 710 |
|
|
2022
Q1 | $8K | Sell |
64
-60
| -48% | -$7.23K | ﹤0.01% | 745 |
|
|
2021
Q4 | $15K | Sell |
124
-16
| -11% | -$2.09K | ﹤0.01% | 699 |
|
|
2021
Q3 | $20K | Hold |
140
| – | – | ﹤0.01% | 710 |
|
|
2021
Q2 | $22K | Buy |
140
+6
| +4% | +$972 | ﹤0.01% | 668 |
|
|
2021
Q1 | $21K | Sell |
134
-48
| -26% | -$7.43K | ﹤0.01% | 654 |
|
|
2020
Q4 | $27K | Sell |
182
-16
| -8% | -$2.26K | ﹤0.01% | 601 |
|
|
2020
Q3 | $26K | Buy |
198
+73
| +58% | +$9.54K | ﹤0.01% | 604 |
|
|
2020
Q2 | $14K | Sell |
125
-7
| -5% | -$807 | ﹤0.01% | 625 |
|
|
2020
Q1 | $13K | Sell |
132
-376
| -74% | -$49.3K | ﹤0.01% | 645 |
|
|
2019
Q4 | $74K | Buy |
508
+44
| +9% | +$6.07K | ﹤0.01% | 645 |
|
|
2019
Q3 | $62K | Buy |
+464
| New | +$59.9K | ﹤0.01% | 635 |
|
|
2015
Q4 | – | Sell |
-2,196,007
| Closed | -$200M | – | 1126 |
|
|
2015
Q3 | $200M | Buy |
2,196,007
+154,274
| +8% | +$15.5M | 0.59% | 36 |
|
|
2015
Q2 | $217M | Buy |
2,041,733
+311,299
| +18% | +$34.4M | 0.59% | 37 |
|
|
2015
Q1 | $197M | Sell |
1,730,434
-210,956
| -11% | -$24.1M | 0.55% | 38 |
|
|
2014
Q4 | $214M | Buy |
1,941,390
+21,408
| +1% | +$2.26M | 0.59% | 40 |
|
|
2014
Q3 | $187M | Sell |
1,919,982
-333,004
| -15% | -$32.8M | 0.55% | 41 |
|
|
2014
Q2 | $227M | Buy |
2,252,986
+113,842
| +5% | +$11.1M | 0.65% | 32 |
|
|
2014
Q1 | $196M | Sell |
2,139,144
-376,347
| -15% | -$34.7M | 0.56% | 39 |
|
|
2013
Q4 | $228M | Buy |
2,515,491
+19,761
| +0.8% | +$1.71M | 0.68% | 24 |
|
|
2013
Q3 | $199M | Buy |
2,495,730
+1,351,164
| +118% | +$106M | 0.64% | 27 |
|
|
2013
Q2 | $83.3K | Buy |
+1,144,566
| New | +$85.6M | 0.3% | 68 |
|
Other funds holding ZBH
Loomis, Sayles & Company's ZBH Position: Q2 2026 in Review
Loomis, Sayles & Company increased its Zimmer Biomet (ZBH) stake by 65% in Q2 2026, buying an estimated $12.8K and bringing the position to 372 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #664.
Loomis, Sayles & Company first reported a position in ZBH in Q2 2013 and has held it in 32 quarters since. The position peaked at $228M in Q4 2013. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.
- Loomis, Sayles & Company held 372 shares of Zimmer Biomet worth $32K as of Q2 2026.
- Loomis, Sayles & Company bought 146 Zimmer Biomet shares in Q2 2026, an estimated $12.8K.
- Zimmer Biomet made up ﹤0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #664 holding.
- Loomis, Sayles & Company first reported a position in Zimmer Biomet in Q2 2013 and has held it in 32 quarters since.
- Loomis, Sayles & Company's Zimmer Biomet position peaked at $228M in Q4 2013.
- 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.
Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.